European equities traded in the US as American depositary receipts were moving higher late Friday morning, up 0.48% to 1,412.34 on the S&P Europe Select ADR Index, which is relatively flat for the week.
From continental Europe, the gainers were led by internet browser company Opera (OPRA) and biopharmaceutical company Genfit (GNFT), which rose 6.8% and 2.5%, respectively. They were followed by 3D printer company Materialise (MTLS) and biotech firm BioNTech (BNTX), which were up 2.4% and 1.4%, respectively.
The decliners from continental Europe were led by biopharmaceutical company DBV Technologies (DBVT) and biotech firm Evaxion Biotech (EVAX), which fell 7.8% and 5.1%, respectively. They were followed by biopharmaceutical company Cellectis (CLLS) and oil and gas company Eni (E), which were down 1.5% and 1.3%, respectively.
From the UK and Ireland, the gainers were led by alcoholic beverage company Diageo (DEO) and financial services company Barclays (BCS), which increased 2% each. They were followed by financial services company HSBC (HSBC) and cruise line operator Carnival (CUK), which were up 1.5% each.
The decliners from the UK and Ireland were led by biopharmaceutical company Akari Therapeutics (AKTX) and pharmaceutical company Silence Therapeutics (SLN), which dropped 4.1% and 3.7%, respectively. They were followed by biotech firm Autolus Therapeutics (AUTL) and biopharmaceutical company TC Biopharm (TCBP), which lost 3.1% and 2.8%, respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.